ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 13,620,000 shares, a growth of 11.8% from the December 15th total of 12,180,000 shares. Based on an average daily volume of 3,500,000 shares, the short-interest ratio is currently 3.9 days.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $16.02 on Monday. The company’s fifty day simple moving average is $19.04 and its 200-day simple moving average is $17.34. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics has a 12 month low of $4.86 and a 12 month high of $23.64. The firm has a market cap of $3.79 billion, a PE ratio of 57.21 and a beta of 0.76.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the business earned $0.01 earnings per share. Equities research analysts expect that ADMA Biologics will post 0.52 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Victory Capital Management Inc. boosted its holdings in shares of ADMA Biologics by 192.6% in the second quarter. Victory Capital Management Inc. now owns 84,046 shares of the biotechnology company’s stock worth $940,000 after acquiring an additional 55,322 shares during the period. Acadian Asset Management LLC purchased a new position in ADMA Biologics in the 2nd quarter worth $93,000. Quest Partners LLC bought a new position in ADMA Biologics during the 2nd quarter worth approximately $29,000. State of New Jersey Common Pension Fund D bought a new position in shares of ADMA Biologics in the second quarter worth approximately $2,212,000. Finally, Renaissance Technologies LLC increased its position in shares of ADMA Biologics by 28.7% in the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after acquiring an additional 575,100 shares during the period. 75.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of analyst reports. Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.